Literature DB >> 8160889

Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure.

R R Brandt1, M M Redfield, L L Aarhus, J A Lewicki, J C Burnett.   

Abstract

Circulating atrial natriuretic factor (ANF) is regulated by clearance receptors (ANFR-C). C-ANF-(4-23) is a ring-deleted analogue of ANF, which binds specifically to ANFR-C. The present studies were undertaken to determine total metabolic (TMCR), pulmonary (PCR), and renal clearance rates (RCR) of ANF in a group of seven mongrel dogs in chronic congestive heart failure (CHF) in comparison with a control group (n = 6). TMCR was not altered in CHF [1,534 +/- 319 vs. control: 1,735 +/- 208 ml/min; P = not significant (NS)] in association with an elevation of circulating endogenous ANF (206 +/- 44 vs. control: 36 +/- 10 pg/ml; P < 0.01). Infusion of C-ANF-(4-23) reduced TMCR in both groups similarly (CHF: 753 +/- 134 vs. control: 972 +/- 156 ml/min; P = NS). PCR was lower in CHF (286 +/- 431 vs. 1,672 +/- 407 ml/min; P < 0.05), whereas RCR was not different (10 +/- 24 vs. control: 15 +/- 25 ml/min; P = NS). ANFR-C blockade did not facilitate urinary sodium excretion in CHF. These studies demonstrate that 1) TMCR does not contribute to elevated endogenous ANF in CHF; 2) total functional activity of the clearance receptor pathway is preserved in CHF; and 3) renal ANF metabolism and the clearance receptor pathway are not linked to the avid sodium retention and renal ANF resistance observed in chronic CHF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160889     DOI: 10.1152/ajpregu.1994.266.3.R936

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

Review 1.  Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases.

Authors:  Johanne Tremblay; Richard Desjardins; David Hum; Jolanta Gutkowska; Pavel Hamet
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

2.  Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2013-04-05       Impact factor: 15.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.